stockrow
Monday 9 November 2026
Export ORMP’s income statement to Excel — free account
Oramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.
- Revenue
- +193.3%
- EPS
- +493.8%
- Free cash flow
- +94.3%
Quarter to June 2026, against a year earlier
3.86
0.03
−0.77%
Follow ORMP
Alert me
Oramed Pharmaceuticals Inc. (ORMP) P/E ratio
As of 6 November 2026, Oramed Pharmaceuticals Inc. (ORMP) trades at a P/E ratio of 0.9×. Over the past ten years it has ranged from 0.0× (September 2025) to 25.6× (February 2024); the current reading is higher than 82% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 1.9× | (89.29%) |
| FY2023 | 17.5× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 25.6×
Ten-year median
0.0×
Current reading's percentile
82
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| PEPG PepGen, Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| ORMP Oramed Pharmaceuticals Inc. | 0.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)